GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Cyclically Adjusted PS Ratio

Molecular Partners AG (XSWX:MOLN) Cyclically Adjusted PS Ratio : 2.37 (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Cyclically Adjusted PS Ratio?

As of today (2024-04-30), Molecular Partners AG's current share price is CHF3.29. Molecular Partners AG's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was CHF1.39. Molecular Partners AG's Cyclically Adjusted PS Ratio for today is 2.37.

The historical rank and industry rank for Molecular Partners AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

XSWX:MOLN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.29   Med: 2.9   Max: 4.28
Current: 2.29

During the past 11 years, Molecular Partners AG's highest Cyclically Adjusted PS Ratio was 4.28. The lowest was 2.29. And the median was 2.90.

XSWX:MOLN's Cyclically Adjusted PS Ratio is ranked better than
68.38% of 506 companies
in the Biotechnology industry
Industry Median: 5.395 vs XSWX:MOLN: 2.29

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Molecular Partners AG's adjusted revenue per share data of for the fiscal year that ended in Dec23 was CHF0.215. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is CHF1.39 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Molecular Partners AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Molecular Partners AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Cyclically Adjusted PS Ratio Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 4.06 2.47

Molecular Partners AG Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.06 - - - 2.47

Competitive Comparison of Molecular Partners AG's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Molecular Partners AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Cyclically Adjusted PS Ratio falls into.



Molecular Partners AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Molecular Partners AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=3.29/1.39
=2.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Molecular Partners AG's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.215/106.4611*106.4611
=0.215

Current CPI (Dec23) = 106.4611.

Molecular Partners AG Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 1.741 100.704 1.841
201512 1.490 99.386 1.596
201612 1.128 99.380 1.208
201712 0.959 100.213 1.019
201812 0.489 100.906 0.516
201912 0.952 101.063 1.003
202012 0.374 100.241 0.397
202112 0.301 101.776 0.315
202212 5.698 104.666 5.796
202312 0.215 106.461 0.215

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Molecular Partners AG  (XSWX:MOLN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Molecular Partners AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

By Stock market mentor Stock market mentor 01-08-2023